Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)

NCT07191717 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT07191717
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07191717 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Minimal Residual Disease Study of Selective Estrogen Receptor Degrader Imlunestrant With Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor Abemaciclib in Patients With ER+ Breast Cancer (MIRI)
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
May 18, 2026
Completion date
April 30, 2031
Enrollment
42 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage i breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iii breast cancer ajcc v8, invasive breast carcinoma, localized estrogen receptor-positive breast carcinoma, localized human epidermal growth factor receptor (her2)-negative breast carcinoma